Selexipag for the treatment of pulmonary arterial hypertension-Reference-Cited by-同舟云学术

Selexipag for the treatment of pulmonary arterial hypertension

Published:2020-12-31 Issue:5 Volume:15 Page:583-595
ISSN:1747-6348
Container-title:Expert Review of Respiratory Medicine
language:en
Short-container-title:Expert Review of Respiratory Medicine

Author:

Genecand Léon¹²,Wacker Julie²³,Beghetti Maurice²³,Lador Frédéric²⁴^ORCID

Affiliation:

1. Internal Medicine Department,Riviera Chablais Hospital, Rennaz, Switzerland

2. Pulmonary Hypertension Program, Geneva University Hospitals, Geneva, Switzerland

3. Paediatric Cardiology Unit, University Hospitals of Geneva, Switzerland; Centre Universitaire Romand De Cardiologie Et Chirurgie Cardiaque Pédiatrique, University of Geneva and Lausanne, Switzerland

4. Department of Medicine Specialties, Division of Pulmonary Diseases, Geneva University Hospitals, Geneva, Switzerland

Publisher

Informa UK Limited

Subject

Public Health, Environmental and Occupational Health,Pulmonary and Respiratory Medicine,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/17476348.2021.1866990

Reference77 articles.

1. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

2. Haemodynamic definitions and updated clinical classification of pulmonary hypertension

3. Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol)

4. Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension

5. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of a Prostacyclin IP Receptor Agonist in Patients With Pulmonary Arterial Hypertension in the Real-world Andalusian Setting: The RAMPHA Study;Clinical Therapeutics;2024-06

2. Ameliorating the Poor Dissolution Rate of Selexipag in Aqueous Acidic Conditions Following Confinement into Mesoporous Silica;Indian Journal of Pharmaceutical Education and Research;2023-10-04

3. Comparing the efficacy and safety of low, medium, and high dosages of selexipag for treating pulmonary hypertension: A systematic review and meta‐analysis;Animal Models and Experimental Medicine;2023-09-23

4. Growing up with Idiopathic Pulmonary Arterial Hypertension: An Arduous Journey;Pediatric Reports;2023-05-05

5. Case report: apatinib plus selexipag as a novel therapy for pulmonary tumor thrombotic microangiopathy accompanied by pulmonary hypertension associated with gastric carcinoma;Medicine;2022-07-15